(New York, USA) DelveInsight’s “Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast
Some of the key facts of the Hidradenitis Suppurativa Market Report:
- The Hidradenitis Suppurativa market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Only HUMIRA is now licenced for the treatment of moderate to severe HS, and as such, it offers the potential for substantial market prospects.
- Epidemiology studies completed for the US and Europe indicated a prevalence rate in the range of 0.2% to 4%. However, the majority of studies have noted drawbacks, including the risk of mild cases going unreported and an estimated 7-year diagnosis delay
- In 2021, it was discovered that there were 1,239,695 Hidradenitis Suppurativa cases in seven major markets. The highest prevalence rates of the disease were found in the United States, where there were 572,057 cases, and the EU-5 countries, where there were 577,721 cases. In Japan, there were 89,917 cases of Hidradenitis Suppurativa in 2021.
- Key Hidradenitis Suppurativa Companies: InflaRx, Novartis, ChemoCentryx, UCB Biopharma, Janssen Pharmaceutical / XBiotech, Aclaris Therapeutics, Boehringer Ingelheim, ACELYRIN Inc., Incyte Corporation, Novartis, AbbVie, MoonLake Immunotherapeutics AG, Phoenicis Therapeutics, Staidson (Beijing) Biopharmaceuticals Co., Ltd, and others
- Key Hidradenitis Suppurativa Therapies: IFX-1, Cosentyx, Secukinumab, Avacopan, Bimekizumab, Bermekimab, Zunsemetinib(ATI-450), Spesolimab, Izokibep, Ruxolitinib, CFZ533, Risankizumab, Sonelokimab (M1095), PTM-001, Upadacitinib, BDB-001 Injection, and others
- The Hidradenitis Suppurativa epidemiology based on gender analyzed that a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM
- The Hidradenitis Suppurativa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hidradenitis Suppurativa pipeline products will significantly revolutionize the Hidradenitis Suppurativa market dynamics.
Hidradenitis Suppurativa Overview
A complex dermatological condition called hidradenitis suppurativa (HS) is characterised by recurrent sore nodules and suppuration in places including the axilla and groyne. It is also known as Acne inversa, and while no biological or pathological test may be used to help with diagnosis, its clinical characteristics and chronic nature can.
Get a Free sample for the Hidradenitis Suppurativa Market Report
Hidradenitis Suppurativa Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hidradenitis Suppurativa Epidemiology Segmentation:
The Hidradenitis Suppurativa market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Hidradenitis Suppurativa
- Prevalent Cases of Hidradenitis Suppurativa by severity
- Gender-specific Prevalence of Hidradenitis Suppurativa
- Diagnosed Cases of Episodic and Chronic Hidradenitis Suppurativa
Download the report to understand which factors are driving Hidradenitis Suppurativa epidemiology trends @ Hidradenitis Suppurativa Epidemiology Forecast
Hidradenitis Suppurativa Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hidradenitis Suppurativa market or expected to get launched during the study period. The analysis covers Hidradenitis Suppurativa market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hidradenitis Suppurativa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hidradenitis Suppurativa Therapies and Key Companies
- IFX-1: InflaRx
- Cosentyx /Secukinumab: Novartis
- Avacopan: ChemoCentryx
- Bimekizumab: UCB Biopharma
- Bermekimab: Janssen Pharmaceutical / XBiotech
- Zunsemetinib(ATI-450): Aclaris Therapeutics
Discover more about therapies set to grab major Hidradenitis Suppurativa market share @ Hidradenitis Suppurativa Treatment Market
Hidradenitis Suppurativa Market Drivers
- Growing Patient Pool
- Increasing Awareness
- Improvement in Healthcare Economy and Affordable Treatment Options
Hidradenitis Suppurativa Market Barriers
- Diagnostic Barriers
- Treatment Cost and Growing Trend of Supportive and Alternative Medicine
Scope of the Hidradenitis Suppurativa Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Hidradenitis Suppurativa Companies: InflaRx, Novartis, ChemoCentryx, UCB Biopharma, Janssen Pharmaceutical / XBiotech, Aclaris Therapeutics, Boehringer Ingelheim, ACELYRIN Inc., Incyte Corporation, Novartis, AbbVie, MoonLake Immunotherapeutics AG, Phoenicis Therapeutics, Staidson (Beijing) Biopharmaceuticals Co., Ltd, and others
- Key Hidradenitis Suppurativa Therapies: IFX-1, Cosentyx, Secukinumab, Avacopan, Bimekizumab, Bermekimab, Zunsemetinib(ATI-450), Spesolimab, Izokibep, Ruxolitinib, CFZ533, Risankizumab, Sonelokimab (M1095), PTM-001, Upadacitinib, BDB-001 Injection, and others
- Hidradenitis Suppurativa Therapeutic Assessment: Hidradenitis Suppurativa current marketed and Hidradenitis Suppurativa emerging therapies
- Hidradenitis Suppurativa Market Dynamics: Hidradenitis Suppurativa market drivers and Hidradenitis Suppurativa market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Hidradenitis Suppurativa Unmet Needs, KOL’s views, Analyst’s views, Hidradenitis Suppurativa Market Access and Reimbursement
To know more about Hidradenitis Suppurativa companies working in the treatment market, visit @ Hidradenitis Suppurativa Clinical Trials and Therapeutic Assessment
Table of Contents
- Hidradenitis Suppurativa Market Report Introduction
- Executive Summary for Hidradenitis Suppurativa
- SWOT analysis of Hidradenitis Suppurativa
- Hidradenitis Suppurativa Patient Share (%) Overview at a Glance
- Hidradenitis Suppurativa Market Overview at a Glance
- Hidradenitis Suppurativa Disease Background and Overview
- Hidradenitis Suppurativa Epidemiology and Patient Population
- Country-Specific Patient Population of Hidradenitis Suppurativa
- Hidradenitis Suppurativa Current Treatment and Medical Practices
- Hidradenitis Suppurativa Unmet Needs
- Hidradenitis Suppurativa Emerging Therapies
- Hidradenitis Suppurativa Market Outlook
- Country-Wise Hidradenitis Suppurativa Market Analysis (2019–2032)
- Hidradenitis Suppurativa Market Access and Reimbursement of Therapies
- Hidradenitis Suppurativa Market Drivers
- Hidradenitis Suppurativa Market Barriers
- Hidradenitis Suppurativa Appendix
- Hidradenitis Suppurativa Report Methodology
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
Related Reports:
Hidradenitis Suppurativa Pipeline
“Hidradenitis Suppurativa Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Hidradenitis Suppurativa market. A detailed picture of the Hidradenitis Suppurativa pipeline landscape is provided, which includes the disease overview and Hidradenitis Suppurativa treatment guidelines.
Hidradenitis Suppurativa Epidemiology
DelveInsight’s ‘Hidradenitis Suppurativa Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Hidradenitis Suppurativa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
DelveInsight’s “Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market
DelveInsight’s “Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
DelveInsight’s “Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027” report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Latest Reports By DelveInsight
Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 |Glioblastoma Market | Alpha-Mannosidosis Market | Astigmatism Market | Autonomic Dysfunction Market | Chronic Gout Market | Corneal Ulcer Market | Hpv-Induced Cancers Market | Meningioma Market | Ocular Motility Disturbance Market | Stable Angina Market | Wilms Tumor Market
To know more about our Consulting Services, Click here: Healthcare Consulting
Recent Blog’s By DelveInsight:
- Insights Into The Cutaneous T-cell Lymphoma Treatment Market
- Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
- Emerging Role of Digital Health in the Field of Oncology
- How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
- How are Technological Trends and Innovations Reshaping the Dementia Care
- Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
- Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
- Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
- Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States